Drugs / IO-202
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05309187 | Apr 2022 → Mar 2024 | cancer | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04372433 | Sep 2020 → Jan 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia | Immune-Onc Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IO-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05309187 ↗ |
| Modality | Monoclonal antibody | “IO-202 is a humanized immunoglobulin G1 monoclonal antibody” PMID 40919482 ↗ Jun 2025 |
| Route | Intravenous | “intravenous (IV) IO-202” NCT04372433 ↗ |
| Target | LILRB4 | “specificity for leukocyte immunoglobulin-like receptor B4 (LILRB4; ILT3)” PMID 40919482 ↗ Jun 2025 |